RT Journal Article SR Electronic T1 Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1721 OP 1726 DO 10.2967/jnumed.111.093674 VO 52 IS 11 A1 Hans-Jürgen Biersack A1 Holger Palmedo A1 Andrej Andris A1 Stefan Rogenhofer A1 Furn F. Knapp A1 Stefan Guhlke A1 Samer Ezziddin A1 Jan Bucerius A1 Dirk von Mallek YR 2011 UL http://jnm.snmjournals.org/content/52/11/1721.abstract AB This retrospective study compared the effects of single and multiple administrations of 186Re-hydroxyethylidenediphosphonate (186Re-HEDP) on palliation and survival of prostate cancer patients presenting with more than 5 skeletal metastases. Methods: A total of 60 patients were divided into 3 groups. Group A (n = 19) consisted of patients who had received a single injection; group B (n = 19), patients who had 2 injections; and group C (n = 22), patients who had 3 or more successive injections. The 188Re-HEDP was prepared using non–carrier-added 188Re obtained from an in-house 188W/188Re generator after dilution with carrier perrhenate. Patients’ data available from the referring physicians—including prostate-specific antigen levels—were entered into a Windows-based matrix and analyzed using a statistical program. The Gleason scores were similar for all 3 groups. Results: Mean survival from the start of treatment was 4.50 ± 0.81 mo (95% confidence interval [CI], 2.92–6.08) for group A, 9.98 ± 2.21 mo (95% CI, 5.65–14.31) for group B, and 15.66 ± 3.23 (95% CI, 9.33–22.0) for group C. Although the 3 groups did not differ in Gleason score, the number of lost life-years was significantly lower in group C than in groups A and B. Pain palliation was achieved in 89.5% of group A, 94.7% of group B, and 90.9% of group C. Conclusion: Posttreatment overall survival could be improved from 4.50 to 15.66 mo by multiple-injection bone-targeted therapy with 188Re-HEDP, when compared with a single injection. Significant pain palliation was common and independent of administration frequency.